title: The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children.
abstract: Characteristics of avian-human (ah) and cold-adapted (ca) influenza A/Kawasaki/9/86 (H1N1) reassortant vaccine viruses were compared in 37 seronegative adults and 122 seronegative infants and children. The 50% human infectious dose (HID50) in infants and children was 10(2.9) and 10(2.6) TCID50 for the ah and ca vaccine, respectively. The ah influenza A/Kawasaki/9/86 reassortant was reactogenic: 24% of infants and children infected with greater than or equal to 100 HID50 had fever greater than or equal to 39.4 degrees C. Since H3N2 ah vaccines were previously shown to be adequately attenuated, it is reasonable to suggest that the genes that code for hemagglutinin and neuraminidase of the H1N1 virus apparently influence the reactogenicity of reassortant viruses derived from the avian influenza A/Mallard/New York/6750/78 donor virus. Because this avian virus does not reproducibly confer a satisfactory level of attenuation to each subtype of influenza A virus, it is not a suitable donor virus for attenuation of wild-type influenza viruses. In contrast, the ca A/Ann Arbor/6/60 donor virus reliably confers attenuation characteristics to a variety of H1N1 and H3N2 influenza A viruses.
authors.affiliation: Department of International Health, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland.
authors.forename: M C
authors.initials: MC
authors.lastname: Steinhoff
authors.forename: N A
authors.initials: NA
authors.lastname: Halsey
authors.forename: L F
authors.initials: LF
authors.lastname: Fries
authors.forename: M H
authors.initials: MH
authors.lastname: Wilson
authors.forename: J
authors.initials: J
authors.lastname: King
authors.forename: B A
authors.initials: BA
authors.lastname: Burns
authors.forename: R K
authors.initials: RK
authors.lastname: Samorodin
authors.forename: V
authors.initials: V
authors.lastname: Perkis
authors.forename: B R
authors.initials: BR
authors.lastname: Murphy
authors.forename: M L
authors.initials: ML
authors.lastname: Clements
mesh_terms: D000328:Adult; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype; D009980:Influenza A virus / Q000276:immunology* / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000009:adverse effects*; D007251:Influenza, Human / Q000209:etiology / Q000517:prevention & control*; D014613:Vaccines, Attenuated / Q000009:adverse effects; D014614:Vaccines, Synthetic / Q000009:adverse effects; D014774:Virulence
chemical_list: D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic